Benedikt von Braunmuehl, newly-appointed CEO at Rentschler Biopharma

Rentschler names Benedikt von Braun­muehl as CEO; Catal­ent grabs David McEr­lane from Lon­za as bi­o­log­ics lead

Benedikt von Braun­muehl has been re­vealed as Rentschler Bio­phar­ma’s new CEO. Mean­while, Catal­ent al­so an­nounced that David McEr­lane is the CD­MO’s new group pres­i­dent of its bi­o­log­ic seg­ment.

Von Braun­muehl, the for­mer CEO of HM­NC Brain Health, re­placed Frank Math­ias, who shift­ed to Ox­ford Bio­med­ica in Feb­ru­ary af­ter sev­en years at Rentschler. Tues­day marks von Braun­muehl’s first day on the job.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.